The Cost Study of Cetuximab and Panitumumab in The First-Line Treatment of Mcrc in The Czech Republic
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.162
https://www.valueinhealthjournal.com/article/S1098-3015(17)30496-5/fulltext
Title :
The Cost Study of Cetuximab and Panitumumab in The First-Line Treatment of Mcrc in The Czech Republic
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30496-5&doi=10.1016/j.jval.2017.08.162
First page :
A426
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
143